Search research articles
Contact Us
Filters
Showing results (51-60 of 118) with videos related to
Page
of 12
Sort By:
The British Journal of Dermatology
|
June 29, 2020
Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial
R B Warren, A Blauvelt, Y Poulin, et al.
The British Journal of Dermatology
|
November 5, 2011
Genetic susceptibility to psoriasis and psoriatic arthritis: implications for therapy
H L Hébert, F R Ali, J Bowes, et al.
Circulation
|
April 1, 1979
Isopotential body surface mapping in subjects of all ages: emphasis on low-level potentials with analysis of the method
M S Spach, R C Barr, R B Warren, et al.
The British Journal of Dermatology
|
March 10, 2016
Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study
A Egeberg, L Mallbris, R B Warren, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
January 31, 2020
Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review
A Al-Janabi, A C Foulkes, K Mason, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
January 22, 2021
Network meta-analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method
U Mrowietz, R B Warren, C L Leonardi, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
September 26, 2020
Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial
R B Warren, J M Carrascosa, E Fumero, et al.
Clinical and Experimental Dermatology
|
May 29, 2018
What's new in psoriasis treatment? An analysis of systematic reviews published in 2015
A C Foulkes, F Ferguson, D J C Grindlay, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
June 30, 2021
Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial
R B Warren, M Lebwohl, H Sofen, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
February 18, 2015
A novel mutation in IL36RN underpins childhood pustular dermatosis
J M Ellingford, G C M Black, T H Clayton, et al.
Page
of 12
Search research articles
Search
Showing results (51-60 of 118) with videos related to
Sort By:
Page
of 12
The British Journal of Dermatology
|
June 29, 2020
Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial
R B Warren, A Blauvelt, Y Poulin, et al.
The British Journal of Dermatology
|
November 5, 2011
Genetic susceptibility to psoriasis and psoriatic arthritis: implications for therapy
H L Hébert, F R Ali, J Bowes, et al.
Circulation
|
April 1, 1979
Isopotential body surface mapping in subjects of all ages: emphasis on low-level potentials with analysis of the method
M S Spach, R C Barr, R B Warren, et al.
The British Journal of Dermatology
|
March 10, 2016
Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study
A Egeberg, L Mallbris, R B Warren, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
January 31, 2020
Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review
A Al-Janabi, A C Foulkes, K Mason, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
January 22, 2021
Network meta-analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method
U Mrowietz, R B Warren, C L Leonardi, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
September 26, 2020
Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial
R B Warren, J M Carrascosa, E Fumero, et al.
Clinical and Experimental Dermatology
|
May 29, 2018
What's new in psoriasis treatment? An analysis of systematic reviews published in 2015
A C Foulkes, F Ferguson, D J C Grindlay, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
June 30, 2021
Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial
R B Warren, M Lebwohl, H Sofen, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
February 18, 2015
A novel mutation in IL36RN underpins childhood pustular dermatosis
J M Ellingford, G C M Black, T H Clayton, et al.
Page
of 12